Table 1.
Demographic, clinical, and neuropathological characteristics by diagnosis
| Clinical diagnosis | Comparison by diagnosis group | |||
|---|---|---|---|---|
| ND | MCI | Total | (P value) | |
| (N = 31) | (N = 13) | (N = 44) | ||
| Age at death (years) | ||||
| Mean ± SD | 83.1 ± 6.1 | 86.2 ± 5.4 | 84.0 ± 6.0 | 0.13# |
| (Range) | (69–97) | (74–95) | (69–97) | |
| Sex | 19 M/12F (61.3% Male) |
8 M/5F (61.5% Male) |
27 M/17F (61.4% Male) | > 0.99‡ |
| Postmortem Interval (hours) | ||||
| Mean ± SD | 2.7 ± 0.6 | 2.7 ± 0.5 | 2.7 ± 0.6 | 0.84# |
| (Range) | (1.5–4.8) | (1.8–3.5) | (1.5–4.8) | |
| MMSE | ||||
| Mean ± SD | 28.5 ± 1.3 | 27.4 ± 2.4 | 28.2 ± 1.7 | 0.34# |
| (Range) | (26–30) | (23–30) | (23–30) | |
| No Score (N) | 8 | 4 | 12 | |
| Braak Stage | ||||
| I | 5 | 3 | 8 | 0.85§ |
| II | 7 | 3 | 10 | |
| III | 19 | 7 | 26 | |
| NIA-Reagan AD Probability Level | ||||
| Not AD (0) | 9 | 4 | 13 | 0.87§ |
| Low (1) | 7 | 2 | 9 | |
| Intermediate (2) | 15 | 7 | 22 | |
| High (3) | 0 | 0 | 0 | |
| Global CERAD Plaque Density | ||||
| None (0) | 9 | 4 | 13^ | 0.96§ |
| Sparse (1) | 7 | 3 | 10$ | |
| Moderate (2) | 8 | 4 | 12$ | |
| Frequent (3) | 7 | 2 | 9$ | |
ND non-demented, MCI mild cognitive impairment, MMSE Mini-Mental State Examination, NIA-Reagan National Institute on Aging-Reagan Institute AD probability level, CERAD Consortium to Establish a Registry for Alzheimer’s disease, AD Alzheimer’s disease. ^primary age-related tauopathy (PART) cases; $non-PART cases; #Mann-Whitney test; ‡Fisher’s exact test; §Chi-square test